Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Personalized Medicine

PUBLISHER: Grand View Research | PRODUCT CODE: 1609977

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1609977

Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Treatment Selection, Monitoring), By Indication (Oncology, Neurology), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Personalized Medicine Biomarkers Market Growth & Trends:

The global personalized medicine biomarkers market size is estimated to reach USD 47.16 billion by 2030, registering a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.

Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.

Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.

Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.

Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.

Personalized Medicine Biomarkers Market Report Highlights:

  • Based on application, the early detection/screening segment is expected to grow at the fastest CAGR owing to the need to provide early treatment to patients.
  • By indication, the oncology segment held the largest market share in 2024, owing to the rising prevalence of cancer and the wide availability of FDA-approved personalized biomarkers tests for cancer
  • North America held the largest market share attributable to the presence of improved healthcare infrastructure, rising prevalence of target diseases, and increasing government funding for innovation in biomarkers.
Show more
Product Code: GVR-4-68039-996-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Indication outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Personalized Medicine Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Rising awareness and importance of predicting prognosis and selection of dose
      • 3.2.1.3. Need to provide early diagnosis and treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory & reimbursement hurdles
  • 3.3. Personalized Medicine Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Personalized Medicine Biomarkers Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Personalized Medicine Biomarkers Market: Indication Movement Analysis
  • 4.3. Personalized Medicine Biomarkers Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Early Detection/Screening
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Diagnosis
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Treatment Selection
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.8. Monitoring
    • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Personalized Medicine Biomarkers Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Personalized Medicine Biomarkers Market: Biomarker Movement Analysis
  • 5.3. Personalized Medicine Biomarkers Market by Biomarker Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Oncology
    • 5.5.1. By Type Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.1. Breast Cancer
        • 5.5.1.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.2. Lung Cancer
        • 5.5.1.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.3. Colon Cancer
        • 5.5.1.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.4. Others
        • 5.5.1.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2. By Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.1. Circulating Tumor Cells
        • 5.5.2.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.2. Circulating Cell-free DNA
        • 5.5.2.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.3. Extracellular Vesicles
        • 5.5.2.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.4. Other Circulating Biomarkers
        • 5.5.2.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Neurology
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Diabetes
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Autoimmune Diseases
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Cardiology
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Personalized Medicine Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company overview
    • 7.4.1. Laboratory Corporation of America Holding
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Quest Diagnostics Incorporated
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Agilent Technologies, Inc
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Genome Medical, Inc
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Coriell Life Sciences
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. NeoGenomics Laboratories
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. FOUNDATION MEDICINE, INC
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Illumina, Inc
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Guardant Health
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
Show more
Product Code: GVR-4-68039-996-3

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 4 Global personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 5 North America personalized medicine biomarkers, by region, 2018 - 2030 (USD Billion)
  • Table 6 North America personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 7 North America personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 8 U.S. personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 9 U.S. personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 10 Canada personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 11 Canada personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 12 Mexico personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 13 Mexico personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 14 Europe personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 16 Europe personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 17 UK personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 18 UK personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 19 Germany personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 20 Germany personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 21 France personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 22 France personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 23 Italy personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 24 Italy personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 25 Spain personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 26 Spain personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 27 Denmark personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 28 Denmark personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 29 Norway personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 30 Norway personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 31 Sweden personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 32 Sweden personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 36 Japan personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 37 Japan personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 38 China personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 39 China personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 40 India personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 41 India personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 42 Australia personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 43 Australia personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 44 South Korea personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 45 South Korea personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 46 Thailand personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 47 Thailand personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 48 Latin America personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 50 Latin America personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 51 Brazil personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 52 Brazil personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 53 Argentina personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 54 Argentina personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 55 Middle East & Africa personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 58 South Africa personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 59 South Africa personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 62 UAE personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 63 UAE personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Personalized medicine biomarkers market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Personalized medicine biomarkers market: Application outlook and key takeaways
  • Fig. 12 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Monitoring circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Personalized medicine biomarkers market: Indication outlook and key takeaways
  • Fig. 17 Personalized medicine biomarkers market: Indication movement analysis
  • Fig. 18 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Autoimmune diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Personalized Medicine Biomarkers Market: Regional outlook and key takeaways
  • Fig. 25 Breast cancer liquid biopsy: Regional movement analysis
  • Fig. 26 Personalized medicine biomarkers market: regional key takeaways (USD Billion)
  • Fig. 27 Personalized medicine biomarkers market: regional outlook, 2023 & 2030 (USD Billion)
  • Fig. 28 North America personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Canada personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Mexico personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Europe personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 UK personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Germany personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 France personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Spain personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Italy personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Norway personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Denmark personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Sweden personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Asia Pacific personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 China personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Japan personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 India personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 South Korea personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 Australia personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Thailand personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Latin America personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Brazil personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Argentina personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Middle East and Africa personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 South Africa personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Saudi Arabia personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UAE personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Kuwait personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 List of key emerging company's/technology disruptors/innovators
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!